Prevalence of lipoatrophy (LA) and lipohypertrophy (LH) and proportion of children on stavudine and on protease inhibitors during each calendar year in the UK and Ireland.

<p>The denominator for calculation of prevalence in each calendar year is presented below the graph.</p

Multivariable model of risk factors associated with Lipohypertrophy.

<p>Multivariable model of risk factors associated with Lipohypertrophy.</p

Description of cases of lipoatrophy (LA) and lipohypertrophy (LH) compared to non-cases.

<p>Description of cases of lipoatrophy (LA) and lipohypertrophy (LH) compared to non-cases.</p

Kaplan-Meier of emergence of LA or LH in children on ART in the UK and Ireland.

<p>Kaplan-Meier of emergence of LA or LH in children on ART in the UK and Ireland.</p

Multivariable model of risk factors associated with Lipoatrophy.

<p>Multivariable model of risk factors associated with Lipoatrophy.</p

Input parameters.

<p><i>Note: EID; early infant HIV diagnosis, ART; antiretroviral therapy, CDC; centre of disease control</i>.</p

Cost and cost-effectiveness of the intervention strategies.

<p>Note: Model assumes 6,000 children born to HIV infected mothers with a risk of HIV transmission of 3.9% and provision of lifelong ART among HIV infected children diagnosed and initiated on therapy. All costs converted to USD using purchasing power parity (17.5 baht per international US dollar).</p

Cost parameters.

<p>Note. All cost estimates were adjusted for inflation up to 2011.</p

Decision tree for HIV diagnosis and treatment strategies.

<p>Decision tree for HIV diagnosis and treatment strategies.</p

Markov model for HIV diagnosis and treatment strategies.

<p>Markov model for HIV diagnosis and treatment strategies.</p